EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice?

The discovery of activating epidermal growth factor receptor (EGFR) mutations and the anaplastic lymphoma kinase gene rearrangement led to significantly improved outcomes with EGFR-tyrosine kinase inhibitors (TKIs) and crizotinib, respectively. These results have revolutionized treatment algorithms in non-small cell lung cancer (NSCLC), which are now, - at least in part-, biomarker-guided. The advantage of this approach is obvious, allowing active treatments to be offered to a selected group of patients who are more likely to benefit.